CYP2W1 Is Highly Expressed in Adrenal Glands and Is Positively Associated with the Response to Mitotane in Adrenocortical Carcinoma by Ronchi, Cristina L. et al.
CYP2W1 Is Highly Expressed in Adrenal Glands and Is
Positively Associated with the Response to Mitotane in
Adrenocortical Carcinoma
Cristina L. Ronchi1*, Silviu Sbiera1, Marco Volante2, Sonja Steinhauer1, Vanessa Scott-Wild3,
Barbara Altieri1, Matthias Kroiss4, Margarita Bala1, Mauro Papotti2, Timo Deutschbein1,
Massimo Terzolo5, Martin Fassnacht1,4, Bruno Allolio1
1 Endocrine and Diabetes Unit, Department of Internal Medicine I, University Hospital, University of Wuerzburg, Wuerzburg, Germany, 2Department of Oncology,
University of Turin, San Luigi Hospital, Turin, Italy, 3 Institute of Pathology, University of Wuerzburg, Wuerzburg, Germany, 4Comprehensive Cancer Center Mainfranken,
University Hospital, University of Wuerzburg, Wuerzburg, Germany, 5Division of Internal Medicine I, University of Turin, San Luigi Hospital, Turin, Italy
Abstract
Background: Adrenocortical tumors comprise frequent adenomas (ACA) and rare carcinomas (ACC). Human cytochrome
P450 2W1 (CYP2W1) is highly expressed in some cancers holding the potential to activate certain drugs into tumor
cytotoxins.
Objective: To investigate the CYP2W1 expression in adrenal samples and its relationship with clinical outcome in ACC.
Material and Methods: CYP2W1 expression was investigated by qRT-PCR in 13 normal adrenal glands, 32 ACA, 25 ACC, and
9 different non-adrenal normal tissue samples and by immunohistochemistry in 352 specimens (23 normal adrenal glands,
33 ACA, 239 ACC, 67 non-adrenal normal or neoplastic samples).
Results: CYP2W1 mRNA expression was absent/low in normal non-adrenal tissues, but high in normal and neoplastic
adrenal glands (all P,0.01 vs non-adrenal normal tissues). Accordingly, CYP2W1 immunoreactivity was absent/low (H-score
0–1) in 72% of non-adrenal normal tissues, but high (H-score 2–3) in 44% of non-adrenal cancers, in 65% of normal adrenal
glands, in 62% of ACAs and in 50% of ACCs (all P,0.001 vs non-adrenal normal tissues), being significantly increased in
steroid-secreting compared to non-secreting tumors. In ACC patients treated with mitotane only, high CYP2W1
immunoreactivity adjusted for ENSAT stage was associated with longer overall survival and time to progression (P,0.05 and
P,0.01, respectively), and with a better response to therapy both as palliative (response/stable disease in 42% vs 6%, P,
0.01) or adjuvant option (absence of disease recurrence in 69% vs 45%, P,0.01).
Conclusion: CYP2W1 is highly expressed in both normal and neoplastic adrenal glands making it a promising tool for
targeted therapy in ACC. Furthermore, CYP2W1 may represent a new predictive marker for the response to mitotane
treatment.
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Introduction
Most tumors of the adrenal cortex are adenomas (ACA),
whereas malignant carcinomas (ACC) are rare. Both types can be
either endocrinologically silent or hormonally active, with steroid
hormone production being present in at least 60% of ACCs [1].
Malignant tumors are highly aggressive with poor prognosis and
an overall survival rate at 5 years of only 25–50% in most series
[2,3,4]. Thus, malignant adrenocortical tumors remain a major
therapeutic challenge and new targets for treatment are urgently
needed [5].
Cytochrome P450 enzymes are a large family of hemeproteins
with several members being involved in specific steps of
steroidogenesis (for instance CYP2B1) or in the metabolism of
drugs and other xenobiotics (e.g. CYP2D6, CYP3A4, CYP2C9).
The human cytochrome P450 2W1 (CYP2W1) enzyme has been
originally classified as ‘‘orphan’’ because information regarding its
physiologic enzymatic function was lacking. CYP2W1 shares some
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substrate affinity and sequence homology with other P450
enzymes, such as CYP1A1, which is involved in the metabolism
of polycyclic aromatic hydrocarbons and associated with higher
lung cancer risk [6]. Recent studies using recombinant CYP2W1
demonstrated broad catalytic activity towards several chemicals,
including bioactivation of procarcinogens like aflatoxin B1,
polycyclic aromatic hydrocarbon dihydrodiols and aromatic
amines [7,8,9]. Furthermore, it seems to be involved in the
oxydation of lysophospholipids and fatty acids [10].
CYP2W1 mRNA and/or protein are known to be highly
expressed during foetal life and in some cancers, particularly colon
cancer, but also adrenocortical, lung and gastric cancers
[11,12,13,14,15]. Only limited data is available on CYP2W1
mRNA expression in various normal adult human tissues [16] and
protein expression has not been specifically investigated in these
tissues.
Taken together, these features make CYP2W1 a potential tool
for cancer therapy [6,15], as it may activate specific prodrugs into
toxic compounds selectively in cancer cells.
No detailed information on CYP2W1 expression in normal and
neoplastic adrenal glands has been reported. We therefore
analysed CYP2W1 expression in a large series of adrenal tissues
with the major aim to assess its prognostic role in adrenocortical
malignancy and to evaluate its predictive potential for the response
to different treatments.
Materials and Methods
Tissue samples
Seventy fresh frozen adrenal tissues (21 normal adrenal glands,
32 ACA, and 25 ACC) were investigated for evaluation of
CYP2W1 mRNA levels. The adrenocortical tumors included both
hormonally active (n = 34) and endocrinologically silent masses
(n = 23). A total of 16 other normal non-adrenal tissues, consisting
of colon (n= 4), liver (n = 4), kidney (n= 3), thyroid (n = 2), lung
(n = 2), and stomach (n= 1) were used as controls.
A total of 429 paraffin-embedded specimens, including 124
standard full slides and 305 samples assembled into six tissue
microarrays (TMAs) from two centers were available for
immunohistochemistry. TMA samples were included in the
analysis only if two or more evaluable cores per patient were
available after the staining procedure. Thus, the final series
included a total of 370 tissue samples as follows: 18 normal adrenal
glands and 5 adrenal hyperplasia, 39 ACA, 240 ACC, 34 non-
adrenal normal tissues, such as uterus (n = 4), stomach (n = 4),
ovary (n = 3), tonsil (n = 3), kidney (n= 3), liver (n = 2), colon
(n = 2), pancreas (n = 2), prostate (n = 2), lung (n = 2), thyroid
(n = 2), breast (n = 2), spleen (n= 1), tongue (n = 1), ileum (n = 1),
and 34 non-adrenocortical tumors, such as pheochromocytoma
(n = 9), colon cancer (n = 4), pancreas cancer (n = 3), breast cancer
(n = 3), hepatocellular carcinoma (n= 3), ovary cancer (n = 2),
prostate cancer (n = 2), pulmonary adenocarcinoma (n= 2), renal
cell carcinoma (n= 2), testicular carcinoma (n = 1), lung cancer
(n = 1), melanoma (n= 1), and lymphoma (n = 1). Among the ACC
samples, 196 were obtained from surgery of the primary tumor, 26
from local recurrences and 18 from distant metastases.
A total of 25 adrenocortical tumor samples with both frozen
tissue and paraffin slides (8 adenomas and 17 carcinomas) were
used for the comparison between CYP2W1 mRNA levels and
immunoreactivity.
Patients and clinical annotations
Clinical parameters, such as sex, age at diagnosis, date of
surgery, tumor size, and results of hormone analysis, and in case of
ACC, tumor stage according to the European Network for the
Study of Adrenal Tumors (ENSAT) classification [17], Weiss
score, Ki67 index, presence and number of distant metastasis, and
detailed follow-up information were collected through the German
ACC and the ENSAT Registry (www.ensat.org/registry, [18]).
Malignancy and hormonal hypersecretion were defined according
to established clinical, biochemical, and morphological criteria
[19]. For the correlation with clinical data, we considered only
ACC samples obtained from primary surgery (n = 196). Concern-
ing the different treatment modalities, 39 patients did not receive
any therapy after surgery (follow up only), 72 patients were treated
with mitotane only (in an adjuvant, n = 36, or in a palliative
setting, n = 36), 64 patients underwent different systemic cytotoxic
chemotherapy regimens (51 of whom in combination with
mitotane), while for 21 patients such data were not available.
Concerning mitotane treatment, the median duration of mitotane
therapy was of 6 months (range 1–71 months) in patients treated
with palliative intent and 41 months (range 5–161 months) in those
treated adiuvantly. The dosage of mitotane ranged between 1 g
and 6 g per day aiming at target serum concentrations between 14
and 20 mg/l. Among the 61 patients treated with systemic
chemotherapy, 40 received a platinum-based treatment in first line
(in 30 as part of the etoposide+doxorubicin+cisplatin (EDP)
regimen), 14 streptozotocin [20]. The objective response to
therapy was retrospectively evaluated in a total of 124 ACC
patients.
The study was approved by the ethics committee of the
University of Wu¨rzburg (No. 93/02 and 88/11) and written
informed consent was obtained from all patients.
Gene expression analysis
CYP2W1 mRNA expression levels were investigated by real-
time quantitative PCR (qRT-PCR). In brief, RNA was isolated
from fresh frozen tissue samples using the RNeasy Lipid Tissue
Minikit (Qiagen, Alameda, CA, USA) and reverse transcribed
using the QuantiTect Reverse Transcription Kit (Qiagen). Two
predesigned Taqman Gene Expression assays for CYP2W1
(Hs00908623_m1, Exon boundary 7–9, and Hs00214994_m1,
Exon boundary 2–3) were purchased from Applied Biosystems
(Darmstadt, Germany). Endogenously expressed b-actin
(Hs9999903_m1) was used for normalization. 40 ng cDNA was
used for each PCR reaction and each sample was performed in
duplicate. Transcript levels were determined using the TaqMan
Gene Expression Master Mix (Applied Biosystems), the CFX96
real-time thermocycler (Bio-rad, Hercules, CA, USA) and Bio-Rad
CFX Manager 2.0 software. Cycling conditions were 95uC for
three min followed by 50 cycles of 95uC for 30 sec, 60uC for
30 sec, and 72uC for 30 sec. Using the DCT method [21], the
gene expression levels were normalized to those of b-actin, as
previously described [22].
Immunohistochemistry
For our analysis, we selected a highly specific rabbit antibody
(Ab) raised against the N-Terminal region of CYP2W1, which is
well suitable for immunohistochemistry (Ab #1, PA5-14900,
Thermo Fisher Scientific Inc., Waltham, MA USA, epitope:
AQDPSPAARWPP). In particular, Ab #1 showed at the
specificity analysis the maximal specificity among the components
of the CYP family (100% specificity for the CYP2W1 isoform 1,
Q8TAV3, UNIPROTKB, www.uniprot.org, and CLC Sequence
Viewer, Version 7, www.clcbio.com/products/clc-sequence-
viewer). Moreover, we tested different available polyclonal
antibodies against CYP2W1 with Western Blot analysis using
microsomal fractions of HEK293 cell lines transfected with
CYP2W1 Expression in Adrenocortical Tumors
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pCMV4-CYP2W1 vector (kindly provided by Prof. Ingelman-
Sundberg, Karolinska Institute, Sweden [15]) as positive control.
In particular, we compared Ab #1 (diluition 1:50) with a rabbit
Ab raised against the C-Terminal region used in several previous
publications and kindly provided by Prof. Ingelman-Sundberg (Ab
#2, diluition 1:1000, epitope: TMRPRAQALCAVPRP)
[11,14,15,23] and with another rabbit Ab raised against an
internal peptide (Santa Cruz Biotechnology Inc., Dallas, Texas,
USA, H-175, sc-98920, 1:200, 175 aminoacids, [24]). With all
three antibodies we detected a specific band of 54 KDa
corresponding to CYP2W1 (and at least one additional band at
70 KDa, Figure S1).
Western Blot analysis. proteins were extracted with RIPA
buffer. Electrophoresis of equal amounts of lysates was performed
in a bis-tris gel system and protein transferred onto a PVDF
membrane by a tank-blotting procedure. The membrane was
blocked with 5% skim milk powder followed by overnight probing
with the different antibodies at 4uC (see above). After three washes,
the membrane was incubated with horseradish peroxidase-labeled
goat anti-rabbit IgG as secondary antibody (1:5000). The antigen-
antibody complex was visualized by enhanced chemiluminescence
using an Amerscham ECL reagent. Normalization of protein levels
was performed by re-probing the blot with an antibody
recognizing human b-actin (Sigma-Aldrich, St. Louis, USA,
1:5000). Autoradiographs were scanned, and the quantification
of individual bands was measured using Image J software (NCBI).
CYP2W1 immunostaining. TMA and full sections were
deparaffinized and immunohistochemical detection was per-
formed using an indirect immunoperoxidase technique after high
temperature antigen retrieval in 10 mM citric acid monohydrate
buffer (pH 6.5) in a pressure cooker for 13 min. Blocking of
unspecific protein-antibody interactions was performed with 20%
human AB serum in PBS for 1 h at RT. Primary antibody was the
Ab #1, used at a dilution of 1:50 at 4uC overnight together with
the N-Universal Negative Control Anti-Rabbit (Dako, Glostrup,
Denmark). For comparison, Ab#2 was also used in a subset of 25
samples (including 8 different normal tissues and 17 different
tumors) at a dilution of 1:500. Signal amplification was achieved
by En-Vision System Labeled Polymer-HRP Anti-Rabbit (Dako)
for 40 min and developed for 10 min with DAB Substrate Kit
(Vector Laboratories, Burlingame, CA, USA) according to the
manufacturer’s instructions. Nuclei were counterstained with
Mayer’s hemalaun for 2 min. For positive controls, sections with
colon cancer, pancreas cancer and prostate cancer were chosen,
while cells of the tumor stroma served as internal negative control.
Microscopic analysis of CYP2W1 immunoreactivity. All
slides were analyzed independently by two investigators blinded to
clinical information (C.L.R. and So. St.). Both nuclear and
cytoplasmic staining was evaluated, and staining intensity was
graded as negative (0), low (1), medium (2), or strong (3). The
percentage of positive tumor cells was calculated for each
specimen and scored 0 if 0% were positive, 0.1 if 1–9% were
positive, 0.5 if 10–49% were positive and 1 if 50% or more were
positive. A semiquantitative H-score was then calculated by
multiplying the staining intensity grading score with the propor-
tion score as described previously [25]. Where discrepancies were
observed, results were jointly assessed by both investigators and the
final score was formed by consensus. Inter-observer agreement was
strong with a Fleiss k-coefficient of 0.878 and a Pearson’s
correlation coefficient of 0.70 (95% CI 0.58–0.78). Some examples
of the CYP2W1 staining in normal and neoplastic tissues are given
in Figure 1.
Statistical analysis
The Fisher’s exact test or the Chi-square test was used to
investigate dichotomic variables, while a two-sided t test (or non-
parametric test) was used to test continuous variables. A non
parametric Kruskal-Wallis test, followed by Bonferroni post-hoc
test, was used for comparison among several groups for non-
normal distributed variables. Correlations and 95% confidence
intervals (95% CI) between different parameters were evaluated by
linear regression analysis. Overall survival (OS) was defined as the
time from the date of primary surgery to specific death or last
follow-up. Disease-free survival (DFS) was defined as the time from
the date of complete tumor resection to the first radiological
evidence of disease relapse or death. Time to progression was
defined as the time from begin of treatment until first radiological
evidence of any kind of disease progression. All survival curves
were obtained by Kaplan-Meier estimates and the differences
between survival curves were assessed by the log-rank (Mantel-
Cox) test. In this context, the RNA expression was considered as a
categorical value (cut-off value for this data set: median value +
2SD). A multivariate regression analysis was performed by Cox
proportional hazard regression model to identify those factors that
might independently influence survival. Statistical analyses were
made using GraphPad Prism (version 5.0, La Jolla, CA, USA) and
SPSS Software (PASW Version 21.0, SPSS Inc., Chicago, IL,
USA). P values ,0.05 were considered as statistically significant.
Results
CYP2W1 is highly expressed in normal and neoplastic
adrenal glands
CYP2W1 mRNA expression was generally very low in non-
adrenal normal tissues (mean DCT6SD: 0.0001260.000059), but
well detectable in normal adrenal glands (0.03560.032, P,0.005,
Figure 2A). These results were consistent for second CYP2W1
assay for qRT-PCR (data not shown). Adrenocortical tumors also
showed a strong mean CYP2W1 expression (ACA=0.02460.027
and ACC=0.01860.023, Figure 2A). However, a subgroup of
ACCs showed low CYP2W1 levels in comparison with NA and
ACA. No statistically significant correlation was observed between
mRNA levels and histological or clinical parameters.
In immunostaining, CYP2W1 expression was mainly localised
in the cytoplasm and was homogeneously distributed, with a
median percentage of positive cells of 80% (range 40 to 100%).
For samples studied both as full slides and in TMA the results
obtained in standard full slides were consistent with those obtained
in the TMA. In concordance with the mRNA analysis, in the
majority of the non-adrenal normal tissues, CYP2W1 immunore-
activity was absent or low (H-score 0–1 in 72%, 2 in 25% and 3 in
3% of cases), whereas it was significantly higher in our series of
non-adrenal cancers (H-score 0–1 in 56%, 2 in 36% and 3 in 8%
of cases, P,0.05 vs normal tissues, Figure 2B). Surprisingly,
CYP2W1 immunoreactivity was even higher in normal adrenal
glands (H-score 0–1 in 35%, 2 in 43% and 3 in 22% of cases, P,
0.005 vs non-adrenal normal tissues), being slightly more intense
in the zona reticularis and fasciculata than in the zona glomerulosa
(Figure 1). Of note, also the adrenal medulla stained positive for
CYP2W1. The CYP2W1 immunoreactivity in both benign and
malignant adrenocortical tumors was similar to that in normal
adrenal glands (Figure 2B). A good correspondence between
CYP2W1 mRNA expression levels and immunoreactivity was
observed in the 25 adrenocortical tumor samples evaluated with
both methods (P,0.001 by Chi-Square test per trend, Figure
S2).
CYP2W1 Expression in Adrenocortical Tumors
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Very similar results in terms of staining intensity were obtained
in the 25 samples (including both normal and neoplastic tissues)
evaluated with both antibodies (Ab#1 and Ab#2). An example
of the staining in normal liver and normal adrenal gland with the
two antibodies is shown in Figure 1.
Among the ACCs, no difference in CYP2W1 expression was
observed between primary tumors (n =H-score 0–1 in 49%, 2 in
33% and 3 in 18% of cases), local recurrences (H-score 0–1 in
41%, 2 in 32% and 3 in 27% of cases), and metastatic tissues (H-
score 0–1 in 57%, 2 in 31% and 3 in 12% of cases).
CYP2W1 immunoreactivity correlates with hormone
secretion and histological parameters
Steroid-secreting ACA (n= 25) exhibited higher CYP2W1
immunostaining than non secreting-tumors (n = 14, P,0.05,
Figure 3A), without any significant difference between cortisol-
(n = 17) and aldosterone-secreting tumors (n = 8). Similarly, ACC
samples with multiple hormone secretion had higher CYP2W1
immunoreactivity than those with single hormone secretion (only
androgen, cortisol or aldosterone) or inactive ACC (Figure 3B).
No significant difference was observed between androgen-,
cortisol- or aldosterone-secreting tumors.
Considering only ACC samples obtained from primary surgery
(n = 196), CYP2W1 immunoreactivity was significantly lower in
tumors with a high Ki67 proliferation index (Ki67.10%, n= 59)
than in those with low Ki67 (n= 56, P,0.005) and in those with a
high Weiss score (Weiss score.6, n = 113) compared to those with
low Weiss score (n = 58, P,0.005, Figure 3C and 3D and
Table 1).
CYP2W1 expression and clinical outcome
In a univariate analysis, CYP2W1 immunoreactivity was not
associated with prognosis for both OS (n= 196 patients from first
surgery, median 71.5 vs 43 months with high and low CYP levels,
respectively, HR=1.22, 95% CI=0.8–1.8, P=0.33) and DFS
(n= 50 patients with complete tumor resection after first surgery,
median 38 vs 27 months, HR=1.42, 95% CI= 0.6–3.2,
P=0.47). When restricting the analysis to patients initially
diagnosed with ENSAT stage 1 and 2, we observed only a slightly
increased OS (n= 86, median 154 vs 110 months, HR=1.59,
95% CI= 0.8–3.2, P=0.20) and DFS for tumors with high
CYP2W1 immunoreactivity (n = 27, median 64 vs 24 months,
HR=2.06, 95% CI=0.7–6.2, P=0.20).
Figure 1. CYP2W1 immunohistochemistry. Examples of CYP2W1 immunostaining in normal tissue (i.e. liver and adrenal gland) and neoplastic
tissues (i.e. lung cancer and adrenocortical carcinoma). A: Staining with a polyclonal antibody from Thermo Scientific (Ab #1); B: Staining with a
polyclonal antibody provided by the Karolinska Institute [11,14,23] (Ab #2). Magnification 20X and 10X.
doi:10.1371/journal.pone.0105855.g001
Figure 2. CYP2W1 expression in adrenal and non-adrenal
tissues. A: Relative mRNA expression levels (normalized to b-actin
using the DCT method, [21]). B: CYP2W1 immunoreactivity evaluated as
H-score (for details see Material and methods section). P values were
evaluated by non parametric Kruskal-Wallis test and Bonferroni post-hoc
test. ACA= adrenocortical adenoma, ACC= adrenocortical carcinoma.
doi:10.1371/journal.pone.0105855.g002
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CYP2W1 immunoreactivity is associated with response to
mitotane treatment
When considering separately the 72 patients with ACC treated
with mitotane only (either as adjuvant or palliative therapy), we
observed a slightly longer OS (median 131 vs 72 months,
HR=1.61, P=0.17, Table 2) and time to progression (TTP,
median 45 vs 24 months, HR=1.37, P=0.29 Table 2) for
tumors with high CYP2W1 immunoreactivity. After adjusting the
log-rank test analysis for the ENSAT tumor stage at diagnosis, the
associations became statistically significant (OS: P=0.025, and
TTP: P=0.002, Figure 4A and 4B). At multivariate analysis
including CYP2W1 levels, ENSAT tumor stage, and Ki67
proliferation index, the impact of CYP2W1 expression on both
Figure 3. Relationship between CYP2W1 immunoreactivity and clinico-pathological parameters. A: Relationship with steroid (cortisol or
aldosterone) secretion in adrenocortical adenomas with available hormonal data (ACA, n= 39). B: Relationship with steroid secretion in adrenocortical
carcinomas with available hormonal data (ACC, n = 141). Multiple hormone secretion: androgen- and cortisol-secretion; single secretion: only
androgen-, cortisol- or aldosterone-secretion. C: Relationship with the proliferation index (Ki67) in adrenocortical carcinomas (ACC, only samples
deriving from primary surgery with known Ki67, n = 115). Legend: high Ki67.10% (median value), low Ki67#10%. D: Relationship with Weiss score in
adrenocortical carcinomas (ACC, only samples deriving from the primary surgery with known Weiss score, n = 171). Legend: high Weiss score.6
(median value), low Weiss score #6.
doi:10.1371/journal.pone.0105855.g003
Table 1. Relationship between CYP2W1 immunoreactivity and baseline clinical or pathological characteristics of patients with
adrenocortical carcinoma (only tumour samples derived from primary surgery, n = 196).
Low CYP2W1
(H-score 0–1)
High CYP2W1
(H-score 2–3) P
N (%) 98 (50) 98 (50) NS
Age – median (yrs) 47.0 49.4 NS
Sex – n male (%) 34 (47) 39 (53) NS
Tumour size – median (cm) 11 13 NS
Tumour stage (ENSAT) – n (%)
1–2 49 (57) 37 (43) ,0.05
3–4 37 (41) 53 (59)
Weiss score - median 6 5 ,0.005
Ki67 index – median (%) 16 11 ,0.005
Overall survival – median (months) 43 53 0.45
DFS/TTP – median (months) 54 96 0.44
*P value with Chi-Square test among different response to treatments.
DFS = disease free survival, TTP = time to progression.
doi:10.1371/journal.pone.0105855.t001
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OS and TTP was statistically significant (HR=3.9, P=0.009 and
HR=4.9, P=0.001, respectively, Table 2). In contrast, no
correlation between CYP2W1 and the clinical outcome was
observed in ACC patients who underwent only follow up (no
pharmacological treatment, n = 39) or who received different
systemic cytotoxic chemotherapy (n = 64).
We next examined mitotane treated patients according to
treatment intention. A trend to better OS was observed in case of
high CYP2W1 immunoreactivity in both the 36 patients treated
adjuvantly (HR=3.6, 95% CI= 0.7–18.1, P=0.11, Figure 5A)
and in the 36 patients treated in a palliative setting (median
survival 45 vs 19 months, HR=1.4, 95% CI= 0.65–3.2,
P=0.37, Figure 5B). Moreover, we investigated the objective
response to treatment in both subgroups. Of note, it was
significantly better in patients with high CYP2W1 expression
(absence of disease recurrence in 69% vs 45% of patients treated
adjuvantly, P=0.001, complete/partial response or stable disease
in 42% vs 6% of patients treated with palliative intention,
P=0.0019, Figure 5C and 5D).
No impact of CYP2W1 immunoreactivity on response to
treatment was observed in the subgroup of ACC patients treated
with different systemic cytotoxic chemotherapies (n = 64).
Discussion
This large study on CYP2W1 expression in adrenal glands
reveals several key findings: we observed a high expression of
CYP2W1 in the majority of adrenocortical tumors, comprising
both adenomas and carcinomas, but also in normal adult adrenal
tissue. Furthermore, CYP2W1 immunoreactivity in adrenocortical
tumors was associated with hormonal activity, with a more
differentiated phenotype and in ACC with better response to
mitotane therapy.
CYP2W1 has been classified as an orphan human cytochrom
P450 enzyme, as its physiological substrate is still unknown. Of
major interest is that high CYP2W1 expression is supposed to be
restricted to foetal tissues and to some cancers [11,12,13,15].
However, expression of CYP2W1 in normal adult tissues is still
under debate. Some papers reported that CYP2W1 is not
expressed in normal adult tissues using dot blot experiments in a
panel of normal tissues including one adrenal probe [6,15], but to
date no systematic investigation has been performed. In contrast,
other studies found an mRNA expression of CYP2W1 also in
several normal adult tissues including spleen, testis, lung, pancreas,
placenta, ovary, thymus, prostate, colon, and small intestine [16].
In agreement with these observations, the human Protein Atlas
web-site describes also CYP2W1 protein expression in normal
tissues, such as Leydig cells, pancreas, stomach, myocytes,
neuronal cells, thyroid and adrenal (www.proteinatlas.org; Version
11.0, [26]. In our investigation, very low mRNA expression and
low CYP2W1 immunoreactivity was detected in non-adrenal
normal samples, while interestingly high levels were definitively
found in normal adult adrenal glands.
The expression of CYP2W1 in normal adrenal raises the
question of a specific function in adrenal physiology. In our
adrenocortical tumors, CYP2W1 was expressed at higher levels in
hormonally active tumors (steroid secreting) than in inactive
tumors, suggesting a possible relationship between the CYP2W1
expression and the hormone production, which needs to be further
evaluated.
Expression of CYP2W1 mRNA has been reported previously in
a small number of adrenal tumors, but no details of the respective
tumor entities were reported [6,15]. While in colon cancer
expression of CYP2W1 occurs in about 30% of cases and is known
to be associated with a poor prognosis, in adrenocortical tumors
we observed a high expression in both benign and malignant
tumors. Furthermore, in ACC it was associated with a lower Ki67
index and a lower Weiss score, suggesting rather a more
differentiated phenotype. Hence, in striking contrast to the
findings in colon cancer, CYP2W1 expression in ACC was not
associated with poor prognosis. Instead, higher CYP2W1 levels
were associated with a slightly better outcome in patients with
early ENSAT stages, suggesting that CYP2W1 may be a possible
favourable prognostic marker.
We are aware that demonstrating expression of CYP enzymes
by immunohystochemistry invariably raises questions concerning
the specificity of the antibodies used. However, the antibody that
we used for immunostaining (Ab #1) has been raised against a
peptide sequence highly specific for CYP2W1 among the CYP
family. Furthermore, we found good agreement between the
degree of mRNA and protein expression (Figure S3) and, finally,
at Western Blot analysis with three different antibodies raised
against different regions of CYP2W1 we consistently detected a
specific band corresponding to CYP2W1 protein in positive
controls from transfected cells.
As it has been demonstrated that CYP2W1 is able to activate a
variety of chemical carcinogens to genotoxic compounds,
CYP2W1 has become a promising tool in targeted therapy for
malignancies expressing this enzyme, as it may allow to specifically
targeting tumor cells with limited systemic toxicity. Accordingly,
some anticancer compounds have been developed, which are
selectively bioactivated by CYP2W1 into potent cytotoxic drugs,
such as AQ4N [27], 5F-203 and GW-610 [12], and duocarmycin
bioprecursors [28,29]. This approach has recently been studied
both in vitro and in vivo demonstrating that the duocarmycin
analog ICT2706 is converted by tumor cells into a potent
cytotoxin inhibiting the growth of human colon cancer xenografts
[28,29]. Of particular interest is the observation of a bystander
effect affecting adjacent cells not expressing CYP2W1 by the
toxins generated in CYP2W1 expressing cells, suggesting a
relevant therapeutic potential of an anti-tumor strategy exploiting
bioactivation by CYP2W1. Current treatment options for ACC
are still largely disappointing [2,30,31] and the high expression of
CYP2W1 in many ACCs indicates that CYP2W1 might become
an intriguing target for tumor specific treatment. We then asked
whether CYP2W1 expression might be related to the response to
different pharmacological treatments for ACC. We did not
observe any relationship between the CYP2W1 expression and
the response to cytotoxic drugs, but surprisingly we found a
significant impact of CYP2W1 levels on the efficacy of the therapy
with mitotane, which is the only drug currently approved for the
treatment of advanced ACC. This finding is particularly intriguing
because specific biomarkers predicting the response to mitotane
are still lacking, except for the gene expression of ribonucleotide
reductase large subunit 1 (RRM1, [32]). Furthermore, it has been
suggested that mitotane needs to be activated in adrenocortical
tissue to exert its adrenotoxic effects [33,34], but the precise
molecular mechanisms by which mitotane exerts its adrenolytic
effects are still largely unknown. Intriguingly, in patients treated
with mitotane alone, we observed a significantly better overall
survival in patients with ENSAT tumor stage 1 or 2 (median
survival: 110 vs 70 months, HR=3.22). An objective response to
mitotane treatment was more likely in patients with high CYP2W1
than in those with low CYP2W1 immunoreactivity, both in a
palliative and an adjuvant setting. On the other hand, no impact
of CYP2W1 on clinical outcome has been observed in tumors
from patients who underwent only follow up (no medication) or
were treated with systemic cytotoxic chemotherapy. These
CYP2W1 Expression in Adrenocortical Tumors
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findings indicate that CYP2W1 expression may serve as new
molecular marker for predicting the response to mitotane therapy,
both as adjuvant or palliative option, in patients with ACC.
Moreover, they could imply a potential role of the enzyme
CYP2W1 in the intra-adrenal metabolism of mitotane. Oxidation
by CYP2W1 might contribute to the activation of mitotane and at
least in part explain its specific activity in malignancies of the
adrenal cortex. Obviously, functional experiments are needed to
establish a role of CYP2W1 for the cytotoxic effects of mitotane in
adrenal cells.
The high expression of CYP2W1 in normal adrenal glands
warrants further attention since it may lead to undesirable drug
effects when prodrugs are used that are activated by CYP2W1.
Adrenocortical drug activation may affect normal adrenal function
and carry a risk of adrenal insufficiency. Although such an effect
has not been reported in mice with human colon cancer xenografts
receiving duocarmycin analogs, specific investigations concerning
steroid secretion or adrenal morphology have not been performed.
On the other hand, mitotane therapy for ACC is also associated
with adrenal insufficiency and hydrocortisone replacement is used
to readily compensate the adrenotoxic effects of mitotane on
steroid secretion.
In summary, a high mRNA expression of CYP2W1 was
observed in both normal and neoplastic adrenal glands and
CYP2W1 immunoreactivity was associated with increased hor-
mone-production and with a more differentiated phenotype.
Furthermore, CYP2W1 levels were related to a better response to
treatment with mitotane, rendering it a possible prognostic marker
Figure 4. Impact of combined CYP2W1 immunohistochemistry and initial ENSAT tumor stage on clinical outcome in patients
affected by adrenocortical carcinoma treated with mitotane only (n=72, including both adjuvant and palliative intention). A: Overall
survival; B: Time to progression (TTP).
doi:10.1371/journal.pone.0105855.g004
Figure 5. Relationship between CYP2W1 immunoreactivity and response to therapy with mitotane only, according to treatment
intention. A: Response to therapy in patients treated in an adjuvant setting (n = 36). B: Objective response to therapy in patients treated in a
palliative setting (n = 32).
doi:10.1371/journal.pone.0105855.g005
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for patients who undergo mitotane therapy. The expression of
CYP2W1 in ACC makes this enzyme a promising drug target, by
taking advantage of its ability to convert nontoxic prodrugs (i.e.
duocarmicyn precursors) into highly potent tumor toxins.
Supporting Information
Figure S1 Results of Western Blot analysis. Western Blot
analysis in three human cortisol-secreting adrenocortical adeno-
mas, in a negative control (NC) and in two positive controls (PC1
and PC2, derived from HEK cell lines transfected with CYP2W1,
[15] with different antibodies (see Material and Methods): A:
CYP2W1 Ab from Thermo Scientific (Ab #1, N-terminal, 1:50,
5 min), B: CYP2W1 Ab provided as a gift by Karolinska Institute
(Ab #2, C-terminal, 1:1000, 20 min), C: CYP2W1 Ab from
Santa Cruz (internal region, 1:200, 4 min).
(TIF)
Figure S2 Relationship between CYP2W1 mRNA and
immunoreactivity in 25 adrenocortical tumors (8 adeno-
mas and 17 carcinomas). The relative mRNA levels are expressed
as quartiles of the DCT values, while the CYP2W1 immunore-
activity is expressed as H-score (see materials and methods
section).
(TIF)
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